These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 33804504)

  • 1. Advancing Personalized Medicine in Common Forms of Parkinson's Disease through Genetics: Current Therapeutics and the Future of Individualized Management.
    Reed X; Schumacher-Schuh A; Hu J; Bandres-Ciga S
    J Pers Med; 2021 Mar; 11(3):. PubMed ID: 33804504
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nonmotor Parkinson's and Future Directions.
    Titova N; Chaudhuri KR
    Int Rev Neurobiol; 2017; 134():1493-1505. PubMed ID: 28805581
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Precision Medicine in Parkinson's Disease: From Genetic Risk Signals to Personalized Therapy.
    Straccia G; Colucci F; Eleopra R; Cilia R
    Brain Sci; 2022 Sep; 12(10):. PubMed ID: 36291241
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How close are we to individualized medicine for Parkinson's disease?
    Kim HJ; Jeon B
    Expert Rev Neurother; 2016 Jul; 16(7):815-30. PubMed ID: 27105072
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Personalized Medicine and Nonmotor Symptoms in Parkinson's Disease.
    Titova N; Chaudhuri KR
    Int Rev Neurobiol; 2017; 134():1257-1281. PubMed ID: 28805572
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Large-scale identification of clinical and genetic predictors of motor progression in patients with newly diagnosed Parkinson's disease: a longitudinal cohort study and validation.
    Latourelle JC; Beste MT; Hadzi TC; Miller RE; Oppenheim JN; Valko MP; Wuest DM; Church BW; Khalil IG; Hayete B; Venuto CS
    Lancet Neurol; 2017 Nov; 16(11):908-916. PubMed ID: 28958801
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Parkinson's genetics research on underrepresented AfrAbia populations: current state and future prospects.
    Mohamed W
    Am J Neurodegener Dis; 2023; 12(2):23-41. PubMed ID: 37213711
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Toward precision medicine in Parkinson's disease.
    Bu LL; Yang K; Xiong WX; Liu FT; Anderson B; Wang Y; Wang J
    Ann Transl Med; 2016 Jan; 4(2):26. PubMed ID: 26889479
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multi-ancestry population attributable risk assessment of common genetic variation in Alzheimer's and Parkinson's diseases.
    Jones L; Cerquera-Cleves C; Schuh AF; Makarious MB; Iwaki H; Nalls MA; Noyce AJ; ; Blauwendraat C; Singleton A; Mata I; Bandres-Ciga S
    medRxiv; 2024 Sep; ():. PubMed ID: 39371162
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emerging perspectives on precision therapy for Parkinson's disease: multidimensional evidence leading to a new breakthrough in personalized medicine.
    Wang Q; Gu X; Yang L; Jiang Y; Zhang J; He J
    Front Aging Neurosci; 2024; 16():1417515. PubMed ID: 39026991
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification and prediction of Parkinson's disease subtypes and progression using machine learning in two cohorts.
    Dadu A; Satone V; Kaur R; Hashemi SH; Leonard H; Iwaki H; Makarious MB; Billingsley KJ; Bandres-Ciga S; Sargent LJ; Noyce AJ; Daneshmand A; Blauwendraat C; Marek K; Scholz SW; Singleton AB; Nalls MA; Campbell RH; Faghri F
    NPJ Parkinsons Dis; 2022 Dec; 8(1):172. PubMed ID: 36526647
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Parkinson's disease: From genetics to molecular dysfunction and targeted therapeutic approaches.
    Huang Y; Wei J; Cooper A; Morris MJ
    Genes Dis; 2023 May; 10(3):786-798. PubMed ID: 37396535
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Parkinson's Disease Subtyping Using Clinical Features and Biomarkers: Literature Review and Preliminary Study of Subtype Clustering.
    Lee SH; Park SM; Yeo SS; Kwon O; Lee MK; Yoo H; Ahn EK; Jang JY; Jang JH
    Diagnostics (Basel); 2022 Jan; 12(1):. PubMed ID: 35054279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A prognostic view on the application of individualized genomics in Parkinson's disease.
    Ross OA
    Curr Genet Med Rep; 2013 Mar; 1(1):52-57. PubMed ID: 23504498
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of the motor and non-motor symptoms in Parkinson's disease according to cluster symptoms presentation.
    Lauretani F; Saginario A; Ceda GP; Galuppo L; Ruffini L; Nardelli A; Maggio M
    Curr Drug Targets; 2014; 15(10):943-7. PubMed ID: 25174438
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacogenetics of antipsychotic-induced movement disorders as a resource for better understanding Parkinson's disease modifier genes.
    Greenbaum L; Lerer B
    Front Neurol; 2015; 6():27. PubMed ID: 25750634
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New Clinical Subtypes of Parkinson Disease and Their Longitudinal Progression: A Prospective Cohort Comparison With Other Phenotypes.
    Fereshtehnejad SM; Romenets SR; Anang JB; Latreille V; Gagnon JF; Postuma RB
    JAMA Neurol; 2015 Aug; 72(8):863-73. PubMed ID: 26076039
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biomarkers for Parkinson's [corrected] disease: tools to assess Parkinson's disease onset and progression.
    Marek K; Jennings D; Tamagnan G; Seibyl J
    Ann Neurol; 2008 Dec; 64 Suppl 2():S111-21. PubMed ID: 19127587
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Perspectives of people living with Parkinson's disease on personalized prediction models.
    van den Heuvel L; Knippenberg M; Post B; Meinders MJ; Bloem BR; Stiggelbout AM
    Health Expect; 2022 Aug; 25(4):1580-1590. PubMed ID: 35608072
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biomarkers in Parkinson's disease: Advances and strategies.
    Delenclos M; Jones DR; McLean PJ; Uitti RJ
    Parkinsonism Relat Disord; 2016 Jan; 22 Suppl 1(Suppl 1):S106-10. PubMed ID: 26439946
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.